{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:24:38Z","timestamp":1787869478796,"version":"build-2784847793"},"reference-count":28,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"25","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) face an unfavorable prognosis once first-line treatment fails; therefore, there is an unmet need for new treatment options. We evaluated the efficacy and safety of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) as an alternative therapy in patients with transplant-ineligible R\/R DLBCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The phase III POLARGO trial was a randomized, open-label, global study. Following a Pola-R-GemOx safety run-in (n = 15), patients with R\/R DLBCL (not otherwise specified or transformed indolent lymphoma) ineligible for autologous stem cell transplant were randomly assigned 1:1 to receive Pola-R-GemOx or R-GemOx alone every 21 days for up to eight cycles. The primary end point was overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      In total, 255 patients were randomly assigned to receive Pola-R-GemOx (n = 129) or R-GemOx (n = 126). After a median follow-up of 24.6 months, patients receiving Pola-R-GemOx versus R-GemOx had a significantly lower risk of death (hazard ratio, 0.6 [95% CI, 0.43 to 0.83];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .0017) with a median OS of 19.5 months (95% CI, 13.3 to not estimable) versus 12.5 months (95% CI, 8.9 to 15.8). The most common grade 3\/4 adverse events (AEs) were thrombocytopenia and neutropenia. Peripheral neuropathy was more common with Pola-R-GemOx (n = 73 [57%]) versus R-GemOx (n = 36 [29%]) and was primarily grade 1. Fatal AEs occurred in 15 (12%) and five (4%) patients in the Pola-R-GemOx and R-GemOx groups, respectively, and were largely driven by infections (including COVID-19).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Pola-R-GemOx significantly improved OS compared with R-GemOx, offering an additional treatment option in patients with transplant-ineligible R\/R DLBCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-02849","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T20:04:18Z","timestamp":1783368258000},"page":"2435-2446","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial"],"prefix":"10.1200","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-3721","authenticated-orcid":false,"given":"Matthew","family":"Matasar","sequence":"first","affiliation":[{"name":"Rutgers Cancer Institute, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8766-1853","authenticated-orcid":false,"given":"Theodoros P.","family":"Vassilakopoulos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-6538","authenticated-orcid":false,"given":"Juan-Manuel","family":"Sancho","sequence":"additional","affiliation":[{"name":"ICO-IJC-HU Germans Trias i Pujol, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9593-6327","authenticated-orcid":false,"given":"Andreas","family":"Viardot","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McMillan","sequence":"additional","affiliation":[{"name":"Center for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[{"name":"University of Health Science, Ankara Oncology Training and Research Hospital, Department of Internal Medicine, Division of Hematology and Stem Cell Transplant Center, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0655-2821","authenticated-orcid":false,"given":"Juliana","family":"Pereira","sequence":"additional","affiliation":[{"name":"Hospital das Clinicas FMUSP, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8986-8436","authenticated-orcid":false,"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[{"name":"Severance Hospital, Yonsei University Health System, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Hematological Disorders and State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-9463","authenticated-orcid":false,"given":"Connie Lee","family":"Batlevi","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana","family":"Hernandez","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"McCall","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Jiang","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Yan","sequence":"additional","affiliation":[{"name":"Hoffmann-La Roche Ltd, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9807-1274","authenticated-orcid":false,"given":"Will","family":"Harris","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Musick","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Department, Henri Mondor University Hospital, Cr\u00e9teil Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"e_1_3_10_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_3_10_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_3_10_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"e_1_3_10_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157729"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00997-w"},{"key":"e_1_3_10_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2321648"},{"key":"e_1_3_10_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.1.84.84"},{"key":"e_1_3_10_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-205500"},{"key":"e_1_3_10_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-066704"},{"key":"e_1_3_10_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"e_1_3_10_13_2","volume-title":"POLIVY\u00ae Summary of Product Characteristics","author":"European Medicines Agency","year":"2025","unstructured":"European Medicines Agency: POLIVY\u00ae Summary of Product Characteristics. 2025"},{"key":"e_1_3_10_14_2","volume-title":"POLIVY\u00ae Prescribing Information","author":"U.S. Food and Drug Administration","year":"2023","unstructured":"U.S. Food and Drug Administration: POLIVY\u00ae Prescribing Information. 2023"},{"key":"e_1_3_10_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00925"},{"key":"e_1_3_10_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"e_1_3_10_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000847620.60858.05"},{"key":"e_1_3_10_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_3_10_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.86"},{"key":"e_1_3_10_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1901090"},{"key":"e_1_3_10_21_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090597"},{"key":"e_1_3_10_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014171"},{"key":"e_1_3_10_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.602"},{"key":"e_1_3_10_24_2","volume-title":"Results of a global randomized phase III trial (STARGLO)","author":"Abrahamson J","year":"2024","unstructured":"Abrahamson J, Ku M, Hertzberg M, et al: Glofitamab plus gemcitabine and oxaliplatin (Glofit-GEMOX) for relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): Results of a global randomized phase III trial (STARGLO). EHA Library, 2024 (abstr LB3438)"},{"key":"e_1_3_10_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02726-5"},{"key":"e_1_3_10_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026830"},{"key":"e_1_3_10_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01957"},{"key":"e_1_3_10_28_2","volume-title":"Bridging Chemotherapy: Relapsed\/Refractory Aggressive B-Cell Lymphoma, the EBMT\/EHA CAR-T Cell Handbook","author":"Thieblemont C","year":"2022","unstructured":"Thieblemont C, Borchmann P: Bridging Chemotherapy: Relapsed\/Refractory Aggressive B-Cell Lymphoma, the EBMT\/EHA CAR-T Cell Handbook. Springer, 2022"},{"key":"e_1_3_10_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01774-4"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-02849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:00:59Z","timestamp":1787868059000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-02849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":28,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["10.1200\/JCO-25-02849"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-02849","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"2025-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}